Benefit of early statin therapy in patients with acute myocardial infarction who have extremely low low-density lipoprotein cholesterol.

[1]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[2]  R. Giugliano,et al.  Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis. , 2008, Journal of the American College of Cardiology.

[3]  G. Lamas,et al.  2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2008, Journal of the American College of Cardiology.

[4]  Christopher E. Buller,et al.  2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2008, Circulation.

[5]  Y. Matsui,et al.  Pravastatin Attenuates Left Ventricular Remodeling and Diastolic Dysfunction in Angiotensin II-Induced Hypertensive Mice , 2008, Journal of cardiovascular pharmacology.

[6]  Á. Avezum,et al.  Comparison of utilization of statin therapy at hospital discharge and six-month outcomes in patients with an acute coronary syndrome and serum low-density lipoprotein>or=100 mg/dl versus<100 mg/dl. , 2007, The American journal of cardiology.

[7]  J. Ornato,et al.  ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patie , 2007, Journal of the American College of Cardiology.

[8]  P. Heidenreich,et al.  Statin Use in Patients With Extremely Low Low-Density Lipoprotein Levels Is Associated With Improved Survival , 2007, Circulation.

[9]  J. Afilalo,et al.  Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials , 2007, Heart.

[10]  T. Villines,et al.  The effect of early, intensive statin therapy on acute coronary syndrome: a meta-analysis of randomized controlled trials. , 2006, Archives of internal medicine.

[11]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[12]  J. D. de Lemos,et al.  Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials. , 2006, JAMA.

[13]  P. Ridker,et al.  Anti-Inflammatory Effects of Statins: Clinical Evidence and Basic Mechanisms , 2005, Nature Reviews Drug Discovery.

[14]  K. Eagle,et al.  Effect of statin use in patients with acute coronary syndromes and a serum low-density lipoprotein, 2005, The American journal of cardiology.

[15]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[16]  Philip J. Barter,et al.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.

[17]  M. Pfeffer,et al.  Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. , 2004, JAMA.

[18]  John Robbins,et al.  National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.

[19]  A. Sposito,et al.  Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[20]  AndrewJ. S. Coats.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial , 2002, The Lancet.

[21]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[22]  R. Rosenson,et al.  Antiatherothrombotic properties of statins: implications for cardiovascular event reduction. , 1998, JAMA.

[23]  B. Davis,et al.  Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial. , 1998, Circulation.

[24]  R. Rosenson,et al.  Myocardial injury: the acute phase response and lipoprotein metabolism. , 1993, Journal of the American College of Cardiology.

[25]  S. Yusuf.  MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary , 2002 .

[26]  ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: executive summary and recommendations. , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.